MedTrace Logo

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

NCT05680220 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-03

No results posted yet for this study

Summary

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation.

In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.

Conditions

Interventions

DEVICE

Neurostimulation System (NSS): Active Setting

Exposure to the active device for 1 hour a day for 6 weeks

DEVICE

Neurostimulation System (NSS): Sham Setting

Exposure to the sham device for 1 hour a day for 6 weeks

Sponsors & Collaborators

  • Technical University of Denmark

    collaborator OTHER

  • OptoCeutics

    collaborator INDUSTRY

  • Klaus Martiny

    lead OTHER

Principal Investigators

  • Klaus Martiny · Senior Consultant at Psychiatric Centre Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2027-06-30
Completion
2027-07-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05680220 on ClinicalTrials.gov